Background: Data from a US multicenter longitudinal study of bariatric surgery were used to compare weight change (primary outcome) and comorbidities (secondary outcome) in patients who underwent sleeve gastrectomy versus Roux-en-Y gastric bypass. Methods: This study includes participants who underwent sleeve gastrectomy and matched participants who underwent Roux-en-Y gastric bypass from the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. Adults undergoing initial bariatric surgical procedures between 2006 and 2009 were enrolled. Participants who underwent sleeve gastrectomy were high-risk or superobese and intended to have a second-stage procedure. Mixed models were used to evaluate percent weight change from baseline through 7 years, and diabetes, dyslipidemia, and hypertension prevalence through 5 years. Results: Fifty-seven of 59 participants who underwent sleeve gastrectomy were matched one to one. Most were female (68%) and white (81%), and had a median age of 49 (37-56) years and median body mass index of 56.4 (35.5-76.8) kg/m 2 presurgery. Weight loss was significantly less 1 to 7 years after sleeve gastrectomy versus matched Roux-en-Y gastric bypass (eg, year 7 mean weight loss was 23.6% vs 30.4%, respectively; P = .001). For both surgical groups, prevalence of diabetes, low high-density lipoprotein, and hypertension were significantly ( P < .05) lower 5 years postsurgery versus baseline. Conclusion: Higher-risk or super-obese participants after sleeve gastrectomy lost less weight than did matched Roux-en-Y gastric bypass counterparts throughout 7 years. Both groups exhibited improvements in comorbidities from presurgery through 5 years.
Introduction
Sleeve gastrectomy (SG) has grown in popularity over the last 2 decades, progressing from investigational to mainstream. 1 Initially, SG was not performed as a primary, definitive bariatric surgical procedure, but rather was intended to be the initial stage of a 2-stage procedure on higher-risk bariatric surgical candidates because of super obesity or complex medical or surgical condi-tions. 2, 3 The second stage was to be either a Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion and duodenal switch after initial weight loss and improved medical status and a decreased operative risk. Early studies demonstrated good preliminary outcomes with this approach. 4 Prior to 2012, SG was not formally accepted as a primary procedure by the American Society of Metabolic and Bariatric Surgery (ASMBS), 5 and many insurers did not cover the procedure. In 2007, the ASMBS expressed support for SG, especially in the 2-stage procedure approach, but cited a lack of greater than 3-year follow-up data as a concern. 6 In 2009, the ASMBS stated there were limited 3-to 5-year data available and conditionally accepted SG, primarily because of its established value as a first-stage operation for high-risk patients. 3 As recently as 2011, the SG accounted for less than one-fifth of bariatric surgical procedures performed in the United States. 7 That same year, a report using national data from the American College of Surgeons-Bariatric Surgery Center Network accreditation program positioned SG between laparoscopic adjustable gastric banding and RYGB in terms of safety, weight loss, and comorbidity resolution in the first postoperative year, 8 which led to formal support from the ASMBS. 5 In 2012, a study of 1,0 0 0 patients who underwent standalone SG with a follow-up of 3 years demonstrated safety, weight, and comorbidities outcomes close to RYGB. 9 Just 4 years later (2016), SG accounted for over one-half of US bariatric surgical procedures. 7 However, there are few prospective studies of SG with long-term follow-up. In addition, there are few comparisons of long-term outcomes after SG versus RYGB, especially among higher-risk, super-obese, or medically complex patients.
The Longitudinal Assessment of Bariatric Surgery-2 (LABS-2), a large multicenter cohort study, was designed to evaluate the effectiveness of surgery, durability of effect, and long-term outcomes. Participants underwent surgery between 20 06 and 20 09 and were followed for 6 to 7 years. The main findings after the 2 most common procedures during that time frame, RYGB and laparoscopic adjustable gastric banding, have been reported. 10 This report addresses an important knowledge gap in the literature by examining the durability and variability of weight loss (primary outcomes) and the comorbidity response (secondary outcomes) after SG, which was performed among super-obese or high-risk patients and originally intended to be the initial stage of a 2-stage process, and compares the response to a matched RYGB group.
Methods
The LABS-2 is a multicenter observational cohort study at 10 US hospitals in 6 geographically diverse clinical centers. Adults undergoing first-time bariatric surgical procedures as part of routine clinical care by participating surgeons were recruited between 2006 and 2009 and followed through January 31, 2015. Research assessments were conducted within 30 days prior to surgery, and approximately 6 months, 1 year, and then annually after surgery for at least 6 years and up to 7 years through the study end date (January 31, 2015). The institutional review boards at each center approved the protocol, and all participants gave informed consent to participate in the study. The LABS study is registered at ClinicalTrials.gov (NCT00465829).
During the time of LABS recruitment (20 06-20 09), SG was recommended to be used as a staged procedure for high-risk or super-obese patients and was not reimbursed as a primary procedure by insurance. All SG submitted into the LABS cohort were designated by their surgeons as "high-risk or superobese" (ie, either high-risk from a medical or surgical perspective) who would significantly benefit from the 2-stage approach.
This report includes 57 participants who underwent a SG and their matched RYGB counterparts. Participants were matched on sex, race, age (within 5 years), and baseline body mass index (BMI) (within 5 kg/m 2 ). Furthermore, when possible, participants were also matched on additional criteria using the following hierarchy: ethnicity, smoking, diabetes, hyperlipidemia, high triglycerides, low high-density lipoprotein (HDL), and hypertension status.
Research assessments, conducted by LABS-certified personnel, were primarily conducted in person, with the exception of the 6-month and 6-year assessments, which were brief, and largely completed by phone or mail. Sociodemographic characteristics were self-reported. Weight measurements and calculation of weight change in the LABS cohort have been described. 10 Weight change was calculated as the percent change from baseline (primary outcome) and in kilograms (secondary outcome). The lowest weight among participants whose weight was measured at 5 or more assessments, at least 1 of which occurred during or after the 5-year assessment, was classified as weight nadir if weight was not missing at the assessments due immediately prior to and immediately after it. Weight regain from nadir was calculated as percentage of maximum weight lost, that is, [100 * (post-nadir weight -nadir weight)]/ (baseline weight -nadir weight) 11 and percentage of baseline weight.
Comorbid conditions were not assessed at the brief assessments conducted at 6 months and year 6 but were at other time points. Given that data collection ended prior to many year 7 assessments and the relatively rare comorbidity outcomes (prevalence, remission, incidence), comorbidities are reported only through year 5. The LABS definitions of diabetes, high low-density lipoprotein cholesterol, low HDL cholesterol, high triglycerides, and hypertension have been reported. 12 In addition to prevalence, remission and incidence of comorbidities at follow-up were determined in reference to baseline status. Remission was defined as having had the comorbidity at baseline with absence of the comorbidity at followup. Incidence was the absence of the comorbidity at baseline and having the comorbidity at follow-up .
Vital status was determined through annual study follow-up. In addition, a query of the National Death Index, a centralized database of death record information on file in state vital statistics offices, was performed through year 2015. 13 Subsequent bariatric procedures within 7 years of initial bariatric surgery were identified by LABS surgeons who performed the procedures, medical record review, or participant self-report, using a standardized protocol.
Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). All reported P values are 2-sided. The data for each participant and his or her match were censored after a second-stage bariatric procedure. Descriptive statistics summarize baseline characteristics, subsequent bariatric procedures, and outcomes by time point in the 2 procedure groups. Frequencies and percentages are reported for categorical data. Medians, 25th and 75th percentiles, are reported for continuous data. Statistical significance of presurgery group differences in distributions was tested using Wilcoxon test for continuous variables and Pearson's χ 2 statistic or exact tests for categorical variables, as appropriate.
Difference in weight change between SG versus RYGB was tested by fitting a linear mixed-effect model via maximum likelihood with weight change over time as the outcome; time since initial bariatric surgery (assessment), procedure (SG versus RYGB), and procedure by time interaction as discrete fixed effects; and the matched pair as random effects. The model controlled for baseline age, smoking, and site, which were related to missing follow-up data 14 as fixed effects. Statistical significance of the difference in distributions of weight change across the 7 years was tested with a likelihood ratio test. Because the procedure by time interaction was significant, the equality of the distributions of weight change at each time point for those undergoing SG versus RYGB were tested. The mean weight change by procedure, and the mean difference in weight change between procedures, with corresponding 95% confidence intervals (CIs), are presented by postsurgery assessment.
A linear mixed-effect model was also used to test for a difference in weight regain from postsurgery weight nadir between SG versus RYGB. Procedure, linear, and quadratic terms for both time since weight nadir (time) and procedure by time interactions were entered as fixed effects, and matched pair as random effects. This model also controlled for baseline age, smoking, and site as fixed effects. Because the procedure by time interactions were not statistically significant, they were not included in final models.
Not all participants undergoing SG could be matched with someone who underwent RYGB by baseline comorbidity status. Because of the small sample size and sparseness of comorbidity data, there were few matched pairs that had data available at the same follow-up time points. Thus the analyses for comorbidities were assessed within each surgical group, using unmatched Poisson mixed models with robust error variance to estimate the prevalence of each comorbidity with time (assessment) as a discrete fixed effect. 15 Modeled proportions and 95% CIs are reported by assessment. Pairwise comparisons were made between baseline and year 5 prevalence. There was insufficient statistical power to model remission and incidence. However, remission and incidence were calculated with observed data.
Results

Study participants and retention
Of 59 participants who underwent a SG procedure, 57 were matched to a participant who underwent RYGB as his or her first bariatric operation; 46 (80.7%) of the RYGB procedures were performed laparoscopically. The 2 participants who could not be matched on sex, age, and BMI were both men: one 35 years of age with a BMI of 80.4 kg/m ² and one 43 years old with a BMI of 94.3 kg/m ². Both participants lost at least 20% of baseline weight by the 6-month assessment and 30% by the year 1 assessment. Neither underwent a subsequent bariatric procedure or died.
Not all participants were due for their 7-year follow-up assessment before data collection ended. In the analysis sample of 57 SG and 57 RYGB, excluding weights after a second-stage bariatric procedure or measured during pregnancy, weights were attained in 98.2% (55/56) of SG participants at 6 months, 100.0% (54/54) at year 1, 89.8% (44/49) at year 2, 87.2% (41/47) at year 3, 89.6% (43/48) at year 4, 80.4% (37/46) at year 5, 93.5% (43/46) at year 6, and 90.0% (27/30) at year 7. Applying the same criteria, among the matched RYGB participants weights were attained 96.5% (55/57) at 6 months, 88.9% (48/54) at year 1, 75.0% (36/48) at year 2, 68.1% (32/47) at year 3, 68.8% (33/48) at year 4, 64.6% (31/48) at year 5, 65.9% (29/44) at year 6, and 57.6% (19/33) at year 7.
Baseline characteristics
Approximately two-thirds of participants were female and 81% were white. The median (25th-75th percentile) age was 49 † The difference is the weight change in SG minus the weight change in RYGB. Thus, a positive number indicates less weight loss after SG versus RYGB. ‡ Estimates are based on a mixed model that controls for baseline age, smoking, and site, which were related to missing follow-up data.
§ P values for model: procedure: < .0 01, time: < .0 01, procedure × time: < .001. Because the procedure by time interaction was statistically significant, the equality of mean change at each time point was tested.
Table 3
Observed percentage of maximum weight lost that was regained * by years since weight nadir.
Years since weight nadir (-25.6 to 18.7) * Data were censored during pregnancies and after a subsequent bariatric procedure or the subsequent bariatric procedure of a match. † The difference between pairs is calculated as the weight regain in SG minus the weight regain in their RYGB matched pair. Of the 57 pairs in the sample, this difference could be calculated among 31 pairs at 1 or more post-nadir assessments. Sixteen pairs were ineligible because at least 1 of the pairs did not regain weight prior to death (2 SG, 1 RYGB), having another procedure (10 SG), or the final LABS-2 assessment (2 SG, 1 RYGB). Ten pairs were excluded because of insufficient weight measurements (2 SG, 6 RYGB, and 2 both SG and RYGB). Weight change Figure 1 shows both modeled and observed percent of baseline weight change by time point and surgical procedure, and the mean difference (ie, SG-RYGB) in weight change between procedures by time point. The difference in weight change between procedures differed over time ( P < .001 for procedure × time interaction). At 6 months there was not a significant difference between SG versus RYGB (estimated mean percent of baseline weight change of 24.1% vs 26.3%; P = .19). However, by year 1 weight change was significantly less after SG compared to RYGB (29.4% vs 34.4%; P < .01) and remained less through year 7 (23.6% vs 30.4%; P = .001).
Supporting data, including weight change in kg, are reported in Table 2 .
Among pairs of participants whose weight nadir could be determined and who gained weight prior to the last study assessment (n = 31; Table 3 ), there was not a significant difference in weight regain from postsurgery weight nadir between surgical groups (ie, SG-RYGB) whether weight regain was measured as the percentage of baseline weight (Beta = 0.53 [95% CI, -2.6 to 3.6]; P = .74) or the percentage of maximum weight lost (Beta = -1.37 [95% CI, -11.7 to 9.0]; P = .79).
Second-stage procedures
Ten participants who underwent SG had a second bariatric procedure during follow-up; all were planned and occurred within 2 years of the initial SG. None of the matched RYGB participants underwent a reversal or second bariatric procedure during follow- up. Information on the participants who underwent a second-stage procedure after SG, including their weight loss prior to the secondstage procedure, is provided in Table 4 . Figure 2 , A and B , shows the modeled prevalence of comorbidities by time point in SG and RYGB, respectively. For both SG and RYGB procedure groups, prevalence of diabetes, low HDL, and hypertension were significantly lower 5 years after surgery versus baseline; high low-density lipoprotein was also significantly lower for RYGB ( Table 5 ), but not SG (44.5 [95% CI, 30.5-58.6] to 24.2 [95% CI, 7.6-40.7]; P = .10). However, statistical power was limited. Likewise, there was not a significant difference in prevalence of high triglycerides between baseline and year 5 for either procedure (23.3 [95% CI, 11.9-34.8] to 7.8 [95% CI, -2.8 to 18.4]; P = .16, for SG; 13.1 [95% CI, 3.9-22.4] to 3.5 [95% CI, -2.4 to 9.3]; P = .17, for RYGB). The observed comorbidity prevalence, remission, and incidence by time point and by surgical procedure are presented in Table 5 .
Comorbid conditions
Mortality and death rates after bariatric surgery
There were 2 deaths within 7 years of SG and 3 deaths within 7 years of RYGB. The SG deaths occurred 8 days and 4.9 years after SG. The RYGB deaths occurred 0.8, 5.2, and 5.7 years after RYGB.
Discussion
This longitudinal study employs standardized data collection and compares weight change through 7 years and comorbidity prevalence through 5 years in a group of super-obese or high-risk patients who underwent laparoscopic SG with a matched group of laparoscopic RYGB. By year 1, weight change was significantly less after SG compared with RYGB and remained less through year 7. There was not a significant difference in weight regained from postsurgery weight nadir by surgical procedure group. For both SG and RYGB, the prevalence of diabetes, low HDL, and hypertension were significantly lower 5 years after surgery versus baseline (eg, diabetes prevalence decreased from 31% to 13% among SG vs 33% to 3% among RYGB).
There are a limited number of studies with up to 5-year outcomes that have focused on the outcomes of higher-risk or super-obese patients who underwent SG, many with the plan of a second-stage definitive procedure to follow. These studies were either retrospective, 16 without comparison group 16 or unmatched [17] [18] [19] or had lacked long-term follow-up. [17] [18] [19] Even so, the reported weight change, weight change comparison, and obesityrelated comorbidity improvement outcomes are similar, for the most part, to this LABS-2 report. For example, Eid et al studied 74 super-obese patients, whose mean preoperative BMI was 66 ± 7 kg/m 2 , who underwent SG but did not proceed to the second weight-loss procedure. 16 This retrospective study, which evaluated status 6 to 8 years (mean: 73 months) postsurgery, reported estimated weight loss of 48%, roughly equivalent to the 7-year weight loss of 24% of baseline weight in our sample. 20 In addition, 70% of the patients with diabetes showed improvement or remission of the disease across follow-up. Although this study had long-term data with 93% data completeness, there was no comparison group, 43% of the outcomes were self-reported, and improvement and remission of diabetes were not reported separately.
Three studies have included RYGB comparison groups. Zerwick et al compared 32 RYGB and 45 SG patients' short-term outcomes (mean preoperative BMIs of 53.9 kg/m 2 and 52.7 kg/m 2 SG and RYGB, respectively). 18 They demonstrated greater weight loss in the RYGB group at 6, 9, and 12 months. Thereaux et al in a singlesite study identified 74 SG (mean BMI 57.2 kg/m 2 ) and 285 RYGB (mean BMI 56.7 kg/m 2 ) patients and compared weight change and diabetes mellitus (DM) improvement at 1 year; RYGB demonstrated better weight loss and resolution of DM. 17 Most recently, Hong et al in a retrospective study identified 106 SG and 501 RYGB patients with a preoperative BMI greater than 50 kg/m 2 with follow-up to 3 years. 19 There was not a statistically significant difference between procedures in the weight loss or rate of type 2 DM remission at any point in the 3-year follow-up period. This study, however, had a very high attrition rate with only 6% of SG group and 11% of RYGB group remaining to complete the 3 years' follow-up time.
Mehaffey et al described outcomes of the 2009 patients undergoing laparoscopic RYGB over 20 years; 328 of them were super super-obese (SSO) with a BMI > 60 kg/m 2 . 21 There was no significant difference in postoperative outcomes or com- Table 5 Observed prevalence, remission, and incidence of comorbidities * and modeled prevalence estimates by time point in relation to initial bariatric procedure, by procedure. 53.6 (37.7-69.5) < .01 * There are 57 SG and 57 RYGB participants. Missing data vary for each comorbid condition because of varying data requirements. † Estimates are based on mixed models that controlled for baseline age, smoking, and site, which were significantly associated with missing follow-up data. NA , not applicable.
plications compared to the non-SSO population. Weight loss was similar to our matched comparator RYGB cohort. However, their follow-up in Mehaffey's SSO cohort decreased to 15% at 4 years.
Recently, 2 randomized clinical trials have compared SG as a standalone procedure versus RYGB. Salminen et al conducted the sleeve-versus-bypass multicenter, randomized clinical equivalence trial in Finland. 22 The trial enrolled 240 morbidly obese patients with mean BMI of 45.9, who were randomly assigned to SG or RYGB with a 5-year follow-up period. The difference in weight loss between the 2 groups was not statistically significant. A similar study from Switzerland (the SM-BOSS randomized clinical trial) also found no significant difference in weight loss in the short term, but weight loss in RYGB participants surpassed SG at 5-year follow-up. 23 These studies, however, were not restricted to superobese or high-risk patients. In addition, they did not show significant statistical difference between SG and RYGB for DM remission. 22, 23 Li et al performed a meta-analysis of 62 studies that included 10,498 RYGB and 7,951 SG patients (preoperative BMI not reported) with follow-up between 0.5 and 5 years. 24 They did not find a significant difference in DM improvement, but concluded that RYGB resulted in greater weight loss and better resolution of hypertension, dyslipidemia, GERD, and arthritis. In another metaanalysis, Shoar and Saber focused on outcomes of 5,264 laparoscopic SG and laparoscopic RYGB patients with 36 to 75.8 months of follow-up. 25 Despite the insignificant difference between RYGB and SG in midterm (3-5 years) weight loss, RYGB produced better weight loss in the long term (greater than 5 years). There was no significant difference between the 2 procedures for comorbidity resolution (type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea).
There are few comparative data on weight regain between bariatric procedures. De Hollanda et al compared midterm (3-5 years) weight-loss trajectories between SG and RYGB, and their data suggested that weight regain was more common after SG. 11 The findings reported here confirm and extend the literature by showing that procedure-specific weight loss diverged 6 months postsurgery, such that the difference between procedures increased until approximately 2 years and then remained relatively consistent through 7 years. Furthermore, with the higher-risk or superobese cohort in LABS reported here, there was not a significant difference in weight regain from nadir by procedure whether measured in reference to baseline weight or in reference to postsurgery weight nadir. Rather, these data suggest it is the weight loss after surgery, as opposed to the weight regain after nadir, that accounts for the difference in long-term weight loss between procedures.
The sample size, inability to match participants on baseline comorbidity status, and discordance in available data throughout follow-up precluded a paired analysis for change in comorbidity prevalence after surgery. However, long-term change in comorbidity status was examined within surgical procedures that had similar sex, race, age, and BMI distributions. This study shows that SG and RYGB were both effective in decreasing prevalence of DM through 5 years of follow-up. The same was true for low HDL and hypertension, although more than half of participants were hypertensive at year 5 (ie, 64%, down from 82% at baseline, among SG, versus 54%, down from 86% at baseline, among RYGB).
Overall, the literature indicates that high-quality studies, including randomized trials with bigger samples, are needed to compare both procedures in high-risk or super-obese patients regarding weight change, obesity-related comorbidity improvement, remission and occurrence, and weight regain outcomes.
This study, although rigorously designed and executed, did have some limitations. Because SG was an uncommon procedure at the time of LABS-2 recruitment, the sample size is small, and most cases were done at 1 site. In addition, because this was an observational (ie, nonrandomized) study, even after matching on key characteristics there may be differences between treatment groups related to change in weight or comorbidities. Data completeness over 7 years was excellent for the SG group (80% or higher) for weight across 6 to 7 years of follow-up. However, it was lower for the matched RYGB group (57%-89%) for unknown reasons. Data completeness for comorbidities was also lower, reflecting the multiple data requirements (ie, fasting blood draw or nonfasting blood draw or blood pressure measurement plus prescription medication assessment). Despite these limitations, this study improves upon previous studies of SG with standardized data collection, a matched RYGB comparator group, and longer-term follow-up.
Conclusion
Higher-risk or super-obese participants after SG lost less weight than matched RYGB counterparts from 1 to 7 years after surgery. Both groups exhibited improvements in comorbidities through 5 years.
Discussion
Dr. Peter Hallowell (Charlottesville, VA): Thank you. Dr. Bestoun, nice presentation. I'd like to thank President Luchette and the Association for the privilege of the floor.
The field of metabolic and bariatric surgery is a shining example of success in modern surgery. Complex operations are performed routinely with unparalleled safety and efficacy in some of the most difficult patients that we as surgeons face. In fact, many patients are denied operations in other fields -orthopedics, hernia, transplant -due to their complexity and high BMI. With many of the short-term issues resolved, bariatric researchers are now reporting on midterm and long-term results of our procedures. The LABS group today reports on their midterm comparative effectiveness of their first cohort of sleeve patients versus gastric bypass patients.
I have a couple of questions for the authors. As you presented the demographics of the two populations today, they are now currently similar to what we see in many academic medical center bariatric surgery programs with average BMI in range as what you have reported. Does the group that you study still represent high-risk patients? How would you now define a group of high-risk patients?
All the patients in the study were planned to have a secondstage procedure, but only approximately 20% proceeded to that second stage. In light of recent data out of Europe showing no difference in weight loss between sleeve and bypass, do you think this had an impact on your results? Based on your data, which procedures do you recommend to your patients? Thank you.
Dr. Bestoun Ahmed: Thank you, Dr. Hallowell. Thank you for your nice comments and kind review of our manuscript.
I do agree with you. That was almost ten years ago. And nowadays we can see a good number of our patients have really higher BMI than before. In fact, I do some cancer practice as well. Even my cancer patients are morbidly obese nowadays which is quite a change from 20 years ago. If I do the same study nowadays, probably the BMI will go to a higher level. When we say high-risk people, we don't mean only the BMI. We mean the number of medical comorbidities, and sometimes the number of surgical interventions on their abdomen. A patient who has three, four hernia repairs, multiple meshes, multiple scars in the abdomen, that may affect my surgical decision, whether I go for sleeve with higher ports in the upper belly or I go with the bypass where I have to work in multiple compartments in the abdomen.
The other question, yes, 20% of our patients have a second-stage procedure. Most of these patients were done in one center, but there were some in other centers as well. Those who had a secondstage procedure also did very well. We have follow-up of those ten patients. One of them lost 50% of their initial weight. Others lost 25% by the first year after their second procedure.
Current bariatric surgery is taking a different trend to having revisional procedures related to problems with the bands, and we are revising nowadays. Currently, 15% of my practice is revisional bariatric surgery, specifically for bands and also for some sleeve patients. I foresee in the future that surgery to revise a bariatric procedure is going to be a trend.
Dr. R. Matthew Walsh (Cleveland, OH): It seems that this isn't exactly the full picture in the sense that part of the stampede, so to speak, for sleeve is the morbidity profile. Can you talk about that in this cohort?
Dr. Bestoun Ahmed: So in this cohort, although we could not match for morbidities because, as I mentioned, we matched for all other demographics. When we came to comorbidity, we needed the same 500 cases of Roux-en-Y patients to be able to match for all the points. That's why we said randomized controlled trials are better. If we review our patients, both the sleeve and bypass groups exhibited significant drop of comorbidities.
Now, that tells us really sleeve is a good procedure, but now the second question, is it as good as gastric bypass in this perspective? I can't answer that with this study. If you review the literature, there's also controversy on that point and there are many good studies, to be honest, coming on. There are two randomized controlled trials, one from Finland and one from Switzerland, comparing small groups, 55 in each arm.
They concluded that there was no significant difference in the resolution of comorbidities between both procedures. So both procedures are good. They didn't favor one over the other, but for the weight change, they concluded long-term weight loss is better for gastric bypass. This was concluded from two other metanalyses, using 62 papers and close to 10,0 0 0 patients. They say initially up to midterm, they may lose the same amount of weight but over long term, bypass supersedes sleeve gastrectomy.
Dr. R. Matthew Walsh (Cleveland, OH): Just to be clear, I was asking about operative morbidity, not comorbidity disease.
Dr. Bestoun Ahmed: Sorry about that. Sleeve gastrectomy is a less invasive procedure, since we are not dealing with the intestine, but the amount of the operation we do on the stomach, to be honest, is more than the gastric bypass. Now, it's less time-consuming and less long-term complications like internal hernias and anastomotic ulcers. We all know now that the incidence of leak is twice as high for sleeve than the gastric bypass.
For this select group of people, we went back and checked for complications. One patient in sleeve group had a suspected leak, and in the bypass group we found no operative complications. So those are the complications and comorbidities we saw.
